What is Picodya?
Founded in 2018, Picodya specializes in the development of a sophisticated in vitro diagnostics platform designed for high-volume, rapid deployment. By bridging the gap between centralized laboratory precision and the immediate needs of point-of-care settings, the company addresses critical bottlenecks in patient triage and clinical decision-making. Its technology is engineered for versatility, supporting seamless integration into hospital departments, field hospitals, and remote clinical facilities, thereby enhancing the efficiency of diagnostic workflows in high-pressure medical environments.
How much funding has Picodya raised?
Picodya has raised a total of $10M across 1 funding round:
Unspecified
$10M
Unspecified (2020): $10M with participation from SIBF
Key Investors in Picodya
SIBF
A venture capital firm focused on identifying and scaling high-growth technology companies with a strong emphasis on industrial and medical innovation.
What's next for Picodya?
With this major enterprise-level funding, Picodya is poised to transition from its foundational development phase into a period of aggressive market expansion and operational scaling. The strategic allocation of this capital will likely focus on optimizing the manufacturing throughput of its diagnostic hardware and expanding its footprint within global healthcare systems. As the demand for decentralized, rapid diagnostic solutions continues to rise, Picodya is well-positioned to leverage its technological infrastructure to capture significant market share, potentially setting a new standard for point-of-care diagnostics in both acute and chronic care management.
See full Picodya company page
